TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESPONSE TO SGX-ST'S QUERY ON UNAUDITED INTERIM RESULTS FOR THE 6-MONTH PERIOD ENDED 30 JUNE 2023

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company", and together with its subsidiaries, the "Group") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

All capitalised terms used herein, unless the context otherwise requires, shall bear the meanings ascribed to them in the HY2023 Results Announcement (as defined below).

The Company has received a query from the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") regarding the Company's unaudited interim results for the 6-month period ended 30 June 2023 ("**HY2023**") announced on 14 August 2023 (the "**HY2023 Results Announcement**"). The Company's response to the query of the SGX-ST are set out below:-

SGX-ST's Query

Please disclose details of the increase in the Company's investment in debt instruments (current and non-current) in 1H2023 as shown at Note 9 of the Company's financial statements, including details such as the issuer of the debt, coupon rate, maturity and other key terms.

Company's Response:

The Company's debt investment is in the form of large bank certificates of deposit. The amount was RMB 82 million at the end of 2022, and RMB 623 million at the end of 2023, showing an increase of RMB 541 million.

The specific details as follows:

Bank name	Annual Interest rate	Maturity date
Industrial Bank Co., Ltd. Tianjin Guangkai Branch	3.10%	22/5/2022
Industrial Bank Co., Ltd. Tianjin Guangkai Branch	3.10%	21/6/2024
China CITIC Bank Corporation Limited Tianjin Heping Branch	3.25%	17/5/2026
China CITIC Bank Corporation Limited Tianjin Heping Branch	3.25%	18/5/2026
China Minsheng Bank Corporation Limited Tianjin Nankai Branch	3.20%	11/5/2026
Zhejiang Commercial Bank Co., Ltd. Tianjin Branch	3.15%	25/5/2026
Industrial Bank Co., Ltd. Tianjin Nankai Branch	3.10%	16/5/2026
Bank of China Co., Ltd. Tianjin Xiguangkai Branch	3.10%	11/5/2026

Industrial and Commercial Bank of China Limited Tianjin Chengdu Road Branch	3.10%	15/5/2026

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
29 August 2023